NETANYA, Israel, June 12, 2019 /PRNewswire/ -- Transseptal
Solutions Ltd., developer of an innovative Transseptal Access
System with a novel approach of transseptal puncture and left
atrial navigation, announced today the completion of the first TSP
Crosser™ transseptal puncture procedure in the US. The
procedure was successfully performed by Dr. Latib, the New
Medical Director of Structural Heart Interventions and
Heart Valve Program at Montefiore-Einstein Center for Heart and
Vascular Care in patient undergoing Percutaneous
Balloon Mitral Valvuloplasty (PBMV) treatment.
"The TSP crosser is an innovative device that facilitates safe,
accurate and reproducible transseptal puncture. We are honored at
Montefiore to be the 1st US center to be utilizing this
device that will be will benefit both novice and expert structural
heart operators," said Dr. Latib.
"It is a major milestone for Transseptal Solutions to launch our
activity in the US, we are very excited for the completion of the
first clinical case with the outstanding Montefiore's structural
heart interventions team," added Elad Sapir, Transseptal Solutions
CEO.
A new approach to the growing need for precise and efficient
access to the left atrium
With the increased availability of transcatheter left atrium
procedures, there is a growing need to provide physicians with
tools that allow accurate, quick and safe access to the left
atrium. TSP Crosser™ is an advanced transseptal
puncture system with a built-in steering mechanism, indicated for
use in procedures where access to the left atrium via transseptal
technique is desired, such as:
- Mitral Valve Repair
- Mitral Valve Replacement
- Paravalvular leak closure
- LAA Closure
- EP Ablation Treatments
TSP Crosser: Transseptal puncture and left atrial navigation
in a single device
The TSP Crosser™
Transseptal Access System combines a sheath, dilator and a flexible
puncturing needle in a single integrated system for controlled LA
access and enhanced performance during transseptal catheterization
procedures. A radiopaque loop wire is positioned at the distal end
of the steerable sheath to aid in the localization of the fossa
ovalis. The flexible puncturing needle and the steerable sheath
allows pre-puncture deflection and orientation, positioning the
needle in the desired puncturing location of the fossa ovalis for
transseptal access. The sheath is steerable up to 180°
bidirectionally after crossing the fossa ovalis. The TSP
Crosser™ has an FDA clearance and CE mark.
"Transseptal catheterization is a critical step for structural
heart and electrophysiology LA interventions," said Elad Sapir,
Transseptal Solutions CEO. "The TSP Crosser™ provides
a stable catheter positioning, with reproducible and controlled
transseptal access, essential for performing accurate transseptal
puncture as part of challenging LA interventions.
About Transseptal Solutions:
Transseptal Solutions
was founded in 2013 and is based in Israel. Transseptal Solutions brings to the
market a new steerable sheath with a novel approach of
transseptal puncture and left atrial navigation. By addressing
significant unmet market needs, Transseptal Solutions seeks to
improve the LA access procedure and generate a novel approach to
serve the expanding indications of left heart treatment.
For more information, please contact:
info@tspmedical.com
www.TransseptalSolutions.com
LinkedIn: https://www.linkedin.com/company/transseptal-solution/
View original content to download
multimedia:http://www.prnewswire.com/news-releases/transseptal-solutions-announces-first-clinical-use-of-tsp-crosser-in-the-united-states-300866331.html
SOURCE Transseptal Solutions Ltd